Abstracts tagged "B cells"

Abstract Number: 2460 • 2015 ACR/ARHP Annual Meeting
B10 Cells May be Involved in Controlling Disease Activity in Polyarticular Juvenile Idiopathic Arthritis Patients
Qianzi Zhao¹ and Lawrence K. Jung², ¹Rheumatology, Children's National Medical Center, Washington, DC, ²Pediatric Rheumatology, Children's National Medical Center, Washington, DC
Background/Purpose: In addition to antibodies production, B cells have been shown to have down-regulatory function on immune response in both mouse and human. The down-regulatory…
Abstract Number: 1096 • 2015 ACR/ARHP Annual Meeting
B Cells Are Prime Producers of Tumor Necrosis Factor Alpha in Rheumatoid Arthritis
Victor Wang¹, Nida Meednu¹, Wen Sun², Javier Rangel-Moreno³, Lianping Xing² and Jennifer H. Anolik¹, ¹Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ²Pathology & Lab Medicine, University of Rochester Medical Center, Rochester, NY, ³Medicine- Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease, which causes joint inflammation and bone loss. Inflammation-mediated joint damage is linked to the imbalance of…
Abstract Number: 1120 • 2015 ACR/ARHP Annual Meeting
Analysis of SLE Plasmablasts By High Throughput Pairing of the Immunoglobulin Heavy and Light Chain (VH-VL)
Deepak Tomar¹, Christopher Tipton¹ and Ignacio Sanz², ¹Medicine/Rheumatology, Emory University School of Medicine, Atlanta, GA, ²Rheumatology, Emory University School of Medicine, Atlanta, GA
Background/Purpose: In-depth analysis of the molecular and antigenic properties of antibody secreting cells (ASC) is critical for our understanding of autoimmune diseases. This goal however…
Abstract Number: 3075 • 2015 ACR/ARHP Annual Meeting
Salivary Gland FcRL4+ B-Cells Are a Potential Source of Progenitor Cells for MALT Lymphoma in Primary Sjögren’s Syndrome
Erlin A. Haacke¹, Frans G.M. Kroese², Philip Kluin³, Petra M. Meiners⁴, Annie Visser⁵, Fred K.L. Spijkervet⁶ and Hendrika Bootsma⁷, ¹Pathology, University Medical Center Groningen, Groningen, Netherlands, ²Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ³Department of Pathology and Medical Biology, UMCG Groningen, Groningen, Netherlands, ⁴Oral and Maxillofacial Surgery, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ⁵Rheumatology and Clinical Immunology, UMC Groningen, Groningen, Netherlands, ⁶Oral and Maxillofacial Surgery, University Medical Center Groningen, Groningen, Netherlands, ⁷Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
Background/Purpose: Patients with primary Sjögren's Syndrome (pSS) have an increased risk of non-Hodgkin's lymphoma, predominantly of the Mucosa Associated Lymphoid Tissue (MALT) type, which commonly…
Abstract Number: 2693 • 2014 ACR/ARHP Annual Meeting
Hyporesponsiveness to TLR9 in Term of Cytokines Production By B Cells in SLE-Patients
Julia Sieber¹, Capucine Daridon¹, Sarah J. Fleischer¹, Vanessa Fleischer¹, Falk Hiepe¹, Tobias Alexander², Guido Heine³, Gerd Burmester⁴, Simon Fillatreau⁵ and Thomas Dörner¹, ¹Charité University Medicine, Dept. Medicine/Rheumatology and Clinical Immunology/German Rheumatism Research Center (DRFZ), Berlin, Germany, ²Dept. Medicine/Rheumatology and Clinical Immunology, Charité University Medicine, Dept. Medicine/Rheumatology and Clinical Immunology/German Rheumatism Research Center (DRFZ), Berlin, Germany, ³Charité University Medicine, Dept. Dermatology, Venerology and Allergology, Berlin, Germany, ⁴Charité University Medicine, Dept. Medicine/Rheumatology and Clinical Immunology, Berlin, Germany, ⁵German Rheumatism Research Center (DRFZ), Berlin, Germany
Background/Purpose The role of B cells in immunity has been mainly related to the generation of antibodies and formation of immune complexes. However, B cells…
Abstract Number: 1938 • 2014 ACR/ARHP Annual Meeting
Effects of Mesenchymal Stem Cells on Human B Cell Proliferation
Erin Collins¹, Maosong Qi² and Gary S. Gilkeson³, ¹Medicine/Rheumatology, Medical University of South Carolina, Charleston, SC, ²Medicine/ Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ³Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC
Background/Purpose: Human mesenchymal stem cells (MSC) are progenitor cells that have immunomodulatory properties. MSCs have been used to treat a variety of autoimmune diseases, including…
Abstract Number: 859 • 2014 ACR/ARHP Annual Meeting
TGF-β3-Producing CD4⁺CD25^–LAG3⁺ Regulatory T Cells Control B Cell Responses
Tomohisa Okamura¹, Kaoru Morita¹, Mariko Inoue¹, Toshihiko Komai¹, Yukiko Iwasaki¹, Shuji Sumitomo¹, Shinichiro Nakachi¹, Hirofumi Shoda², Keishi Fujio² and Kazuhiko Yamamoto¹, ¹Department of Allergy and Rheumatology, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan, ²Department of Allergy and Rheumatology, The University of Tokyo, Tokyo, Japan
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by autoantibody production and associated with a wide range of clinical manifestations. Recent case-control association…
Abstract Number: 2691 • 2014 ACR/ARHP Annual Meeting
A Novel CD123^–CD11c^– Dendritic Cell Subset Increased in Relation to Disease Activity in Patients with Systemic Lupus Erythematosus
Satoshi Kubo¹, Shingo Nakayamada¹, Naoki Yunoue¹, Maiko Yoshikawa¹, Kunihiro Yamaoka¹ and Yoshiya Tanaka², ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
Background/Purpose Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by overproduction of autoantibodies by B cells and breaking self-tolerance of T cells and dendritic…
Abstract Number: 1754 • 2014 ACR/ARHP Annual Meeting
Peripheral CD5⁺b-Cells in ANCA-Associated Vasculitis
Sebastian Unizony¹, Noha Lim², Vincent Carey³, Deborah J. Phippard², Nadia Tchao², Eli M. Miloslavsky⁴, Peter A. Merkel⁵, Paul Monach⁶, William St. Clair⁷, Robert F. Spiera⁸, Adam Asare², Philip Seo⁹, Carol A. Langford¹⁰, Gary S. Hoffman¹¹, Cees Kallenberg¹², Ulrich Specks¹³ and John H. Stone⁴, ¹Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, ²Immune Tolerance Network, Bethesda, MD, ³Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, ⁴Rheumatology, Massachusetts General Hospital, Boston, MA, ⁵Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁶Rheumatology, Boston University, Boston, MA, ⁷Rheumatology and Immunology, Duke University, Durham, NC, ⁸Rheumatology, Hospital for Special Surgery, New York, NY, ⁹Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ¹⁰Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ¹¹Rheumatic & Immunologic Dis, Cleveland Clinic Foundation, Cleveland, OH, ¹²Rheumatology and Clinical Immunology, University of Groningen, Groningen, Netherlands, ¹³Frederichs Dr NW, Mayo Clinic, Rochester, MN
Background/Purpose We explored the utility of peripheral CD19+ CD5+ B-cells (CD5+ B-cells) as biomarkers in ANCA-associated vasculitis (AAV) Methods CD5+ B-cells were measured longitudinally by…
Abstract Number: 858 • 2014 ACR/ARHP Annual Meeting
ABT-199, a Potent and Selective BCL-2 Inhibitor, Prevents Lupus Nephritis in the Spontaneous NZB/W F1 Mouse Model By Depleting Selective Lymphocyte Populations While Sparing Platelets
Li Chun Wang¹, Stuart Perper¹, Annette Schwartz², Christian Goess³, Liz O'connor⁴, Dawna Hartman², Candace Graff², Andrew Souers⁵, Joel Leverson⁵, Steven Elmore⁵ and Lisa Olson², ¹Immunology, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ²AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ³Pharmacology, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ⁴Toxicology, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ⁵AbbVie Inc, North Chicago, IL
Background/Purpose Proteins in the BCL-2 family are key regulators of apoptosis, or programmed cell death. Navitoclax, a selective inhibitor of both BCL-2 and BCL-X(L) demonstrated…
Abstract Number: 2185 • 2014 ACR/ARHP Annual Meeting
Alterations in B Cell Complement Processing Related to a Lupus-Associated Variant in Complement Receptor 2
Brendan M. Giles¹ and Susan A. Boackle², ¹University of Colorado School of Medicine, Aurora, CO, ²Medicine/Rheumatology, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: We have recently identified a variant in intron 1 of complement receptor 2 (CR2/CD21) that is associated with decreased risk of lupus (rs1876453; Pmeta=4.2×10-4,…
Abstract Number: 1718 • 2014 ACR/ARHP Annual Meeting
B Cell Subsets Homeostasis and Functional Properties Are Altered in a Murine Model of Systemic Sclerosis
Sébastien Sanges^1,2,3, Niloufar Kavian⁴, Carine Hauspie^1,3,5, Carole Nicco⁴, Thomas Guerrier^1,3, Virginie Dutoit-Lefèvre^1,3, Guillaume Lefèvre^1,2,5,6, Alexandra Forestier^1,2,3, Vincent Sobanski^1,2,6, Christelle Faveeuw⁷, Myriam Labalette^1,3,5, Frédéric Batteux⁴, David Launay^1,2,3 and Sylvain Dubucquoi^1,3,5, ¹Université Lille Nord de France, Faculté de Médecine Henri Warembourg, Lille, Lille, France, ²Service de médecine interne, Centre National de Référence de la Sclérodermie Systémique, Hôpital Claude Huriez, CHRU Lille, Lille, France, ³EA 2686, Lille, Lille, France, ⁴Université Paris Descartes, EA 1833, Hôpital Cochin, AP-HP, Paris, Paris, France, ⁵Institut d’Immunologie, Centre de Biologie-Pathologie-Génétique, CHRU Lille, Lille, France, ⁶EA 2686, Lille, LILLE, France, ⁷Institut National de la Santé et de la Recherche Médicale Unité 547, Institut Pasteur de Lille, Institut Fédératif de Recherche 142, Université de Lille Nord de France, Lille, France
Background/Purpose Systemic sclerosis (SSc) is a multi-organ fibrotic disease associated with auto-immune abnormalities. Several clinical and experimental observations suggest that B cells are involved in…
Abstract Number: 756 • 2014 ACR/ARHP Annual Meeting
Nucleosome, a Basic Repeating Unit of Chromatin, in Patients with Systemic Sclerosis: Possible Association with Immunological Abnormalities Via Abnormal Activation of T and B Cells
Ayumi Yoshizaki¹, Yoshihide Asano², Takashi Taniguchi¹, Ryosuke Saigusa¹, Kouki Nakamura¹, Takashi Yamashita¹, Takehiro Takahashi¹, Tetsuo Toyama¹, Yohei Ichimura¹, Zenshiro Tamaki¹, Miki Miyazaki¹ and Shinichi Sato¹, ¹Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan, ²University of Tokyo Graduate School of Medicine, Tokyo, Japan
Background/Purpose Nucleosome is the basic repeating units of chromatin. Each nucleosome is composed of an inner core of histones H3 and H4 and an outer…
Abstract Number: 1951 • 2014 ACR/ARHP Annual Meeting
A Novel CD27^(-) Spleen Tyrosine Kinase (Syk) Bright Memory B-Cell Subset Is Expanded in SLE
Sarah Fleischer¹, Claudia Giesecke¹, Henrik Mei¹, Peter E. Lipsky², Capucine Daridon³ and Thomas Dörner³, ¹Charité University Medicine Berlin, CC12, Dept. Medicine/Rheumatology and Clinical Immunology and German Rheumatism Research Center Berlin (DRFZ), Berlin, Germany, Berlin, Germany, ²Peking Union Medical College Hospital, Beijing, China, ³CC12, Dept. Medicine/Rheumatology and Clinical Immunology, Charité University Medicine Berlin, Berlin, Germany
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease known to be associated with a breakdown of self-tolerance, B-cell hyperactivity and disturbed B-cell homeostasis of…
Abstract Number: 1623 • 2014 ACR/ARHP Annual Meeting
Increased CD95 (Fas) Expression on Naive B Cells Is Associated with a Switch to Double Negative and Plasma Cells in the Peripheral Blood, and Correlates with Disease Activity in Systemic Lupus Erythematosus
Julie Ducreux¹, Séverine Nieuwland², Frédéric A. Houssiau¹ and Bernard R. Lauwerys¹, ¹Institut de Recherche Expérimentale et Clinique, Pôle de Maladies Rhumatismales, Université catholique de Louvain, Brussels, Belgium, ²Institut de Recherche Expérimentale et Clinique, Pôle de pathologies rhumatismales, Université catholique de Louvain, Brussels, Belgium
Background/Purpose: systemic lupus erythematosus (SLE) is characterized by a break of tolerance to autoantigens, and polyclonal activation of B cells. We performed multicolor flow cytometry…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].